The Food and Drug Administration (FDA) has approved Ruzurgi (amifampridine; Jacobus Pharmaceutical) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to <17 years of age.
Preliminary findings showed the decrease in botulinum toxin type A therapeutic effect over time warrants further study.
Cigarette smoking is associated with more severe multiple sclerosis disease course with lower lifetime cigarette smoking load and smoking cessation having no significant effect on disease severity.
Guidance has been updated for the health supervision of children with neurofibromatosis type 1.
Alexion announced the publication of data from the phase 3 open-label extension of the REGAIN trial (ECU-MG-302) that assessed the long-term safety and efficacy of eculizumab (Soliris) for the treatment of adults with anti-acetylcholine receptor (AChR) antibody-positive refractory generalized myasthenia gravis (gMG).
A 19-year-old woman with a history of migraine headaches initially presented with subacute onset of double vision and vertigo.The following case study was provided by Daniel Ontaneda, MD, and Marisa McGinley, DO, both neurologists at the Cleveland Clinic in Ohio. In addition, Dr Ontaneda is a co-primary investigator of the international Determining the Effectiveness of…
The management of symptoms of anxiety and of depression in patients with MS is key to mitigating their effect on cognition and functioning.
No significant associations were found between atorvastatin treatment and time to first relapse.
First symptoms and disease type are contributors to delays in multiple sclerosis diagnosis.
The FDA has accepted for review the New Drug Application for a novel oral fumarate candidate, diroximel fumarate, for the treatment of relapsing forms of multiple sclerosis.
